Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke

Phase 1WithdrawnNCT02065778

Neurogen Brain and Spine Institute

Overview

The purpose of this study was to study the safety and effect of stem cell therapy on the functional recovery in patients with chronic stroke.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Cerebrovascular Accident

Interventions

Autologous bone marrow mononuclear cell transplantationBIOLOGICAL

bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * males and females * above 18 years of age * diagnosed as stroke by clinical and MRI findings Exclusion Criteria: * presence of respiratory distress * presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * acute medical conditions such as respiratory infection, fever * hemoglobin less than 8 * bleeding tendency * bone marrow disorder * left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Locations (1)

Neurogen brain and spine institute

Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

Functional Independence Measure

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.